Cogent Biosciences (COGT) Operating Income (2017 - 2026)

Cogent Biosciences' Operating Income history runs 10 years deep, the most recent figure standing at -$103.6 million for Q1 2026.

• In Q1 2026, Operating Income fell 38.27% year-over-year to -$103.6 million; the TTM figure through Mar 2026 stood at -$362.0 million (down 25.5% YoY), while the FY2025 annual figure was -$333.4 million, down 20.81% from the prior year.
• Operating Income was -$103.6 million for Q1 2026 at Cogent Biosciences, down from -$99.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$31.4 million in Q1 2022 to a low of -$103.6 million in Q1 2026.
• Historically, Operating Income has averaged -$62.9 million across 5 years, with a median of -$62.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Income plunged 145.45% in 2022, then dropped 10.53% in 2025.
• A 5-year view of Operating Income shows it stood at -$43.7 million in 2022, then plunged by 33.11% to -$58.2 million in 2023, then slipped by 26.63% to -$73.7 million in 2024, then slumped by 34.94% to -$99.5 million in 2025, then declined by 4.13% to -$103.6 million in 2026.
• The last three Operating Income figures came in at -$103.6 million (Q1 2026), -$99.5 million (Q4 2025), and -$83.4 million (Q3 2025), per Business Quant data.